Skip to content

Kodiak Sciences Inc KOD Operating lease liabilities

Operating lease liabilities at other companies

Ocular Therapeutix logo
Ocular TherapeutixOCUL
Vera Therapeutics logo
Vera TherapeuticsVERA
PVL
Palvella TherapeuticsPVLA
Roivant Sciences logo
Roivant SciencesROIV

Other financials

Income statement

See full
Operating income-$59.8M-1.2%
Net income-$58.2M-1.2%
EPS (diluted)-$0.94+13.8%

Balance sheet

See full
Cash & equivalents$169.5M+22.1%
Total debt$56.0M-17.2%
Total equity$112.1M+3.0%
Total assets$306.0M+2.7%

Cash flow

See full
Operating cash flow-$40.0M-37.6%
CapEx$942.0K+249%
Free cash flow-$41.0M-39.5%

Valuation

See full
Market cap$2.32B+1,477%
Enterprise value$2.2B+2,798%

Returns & leverage

See full
Return on equity-208.8%+2,306pp
Debt / equity0.5×-0.1×
Current ratio3.5×-1.1×

Where this comes from

Reported directly by Kodiak Sciences Inc in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: Kodiak Sciences Inc’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kodiak Sciences Inc's operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kodiak Sciences Inc's operating lease liabilities?
Kodiak Sciences Inc (KOD) reported operating lease liabilities of -$3.19M in Q1 2026.
How has Kodiak Sciences Inc's operating lease liabilities changed year-over-year?
Kodiak Sciences Inc's operating lease liabilities decreased by 17.8% year-over-year, from -$2.71M to -$3.19M.
What is the long-term trend for Kodiak Sciences Inc's operating lease liabilities?
Over 4 years (2021 to 2025), Kodiak Sciences Inc's operating lease liabilities has grown at a 57.5% compound annual growth rate (CAGR), from $1.81M to -$11.17M.